e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Small airways, long distances and large databases in paediatric asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Using remote directly observed therapy (R-DOT) for optimising asthma therapy.
M. Shields (Belfast, United Kingdom)
Source:
International Congress 2017 – Small airways, long distances and large databases in paediatric asthma
Session:
Small airways, long distances and large databases in paediatric asthma
Session type:
Oral Presentation
Number:
3448
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Shields (Belfast, United Kingdom). Using remote directly observed therapy (R-DOT) for optimising asthma therapy.. 3448
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years
Source: Eur Respir J 2004; 24: Suppl. 48, 653s
Year: 2004
Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
Characterization of physical activity (PA) patterns by use of multiple accelerometers in COPD patients undergoing long-term oxygen therapy (LTOT) within a pulmonary rehabilitation (PR) program
Source: Annual Congress 2010 - Physical activity, exercise regimes and outcomes for chronic respiratory disease
Year: 2010
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
Improving asthma therapy through targeting more effective control of inflammation - a European consensus
Source: Eur Respir J 2005; 26: Suppl. 49, 253s
Year: 2005
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Suboptimal asthma control in patients receiving long-term maintenance therapy
Source: Annual Congress 2006 - The challenges of managing asthma in primary care
Year: 2006
Does combination therapy lead to better adherence in asthma?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Combination therapy versus separate therapy in real-life primary care asthma patients
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA).
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Managing asthma patients: which outcomes matter?
Source: Eur Respir Rev 2008; 17: 53-61
Year: 2008
The importance of the aplication long-therm therapy (LTOT) in COPD tretmant
Source: Eur Respir J 2006; 28: Suppl. 50, 519s
Year: 2006
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Is occupational therapy (OT) really needed in pulmonary rehabilitation programmes (PRP)?
Source: Eur Respir J 2005; 26: Suppl. 49, 529s
Year: 2005
Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept